Molecular Analysis and Treatment Options of SCLC

Launched by SHANGHAI CHEST HOSPITAL · Jul 6, 2023

Keywords

ClinConnect Summary

This clinical trial is studying small cell lung cancer (SCLC), a fast-growing cancer that often spreads quickly and is challenging to treat. While patients usually respond well to initial chemotherapy, many experience a relapse, leading to a need for better treatment options. The researchers are focusing on understanding the genetic changes in SCLC and how these might help predict which treatments will work best for individual patients. By creating a registry of patients with SCLC, they hope to gather important information about these genetic markers to improve future therapies and outcomes.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of SCLC. They should also be able to understand the study and agree to participate by signing a consent form. This trial is currently open for recruitment, and it welcomes participants of all genders. Those who join can expect to contribute to important research that aims to uncover new treatment possibilities for SCLC, which could ultimately lead to better care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically proven diagnosis of SCLC
• • 18 years of age or older
• • Ability to understand and the willingness to sign a written informed consent document
• Exclusion Criteria:
• • Histologically proven diagnosis of non-SCLC